^(89)SrCl_2和/或骨膦治疗多发性骨转移癌的临床研究

Separate and combined uses of ^(89)XrCl_2 and Bonefos in the treatment of bone metastatic cancer: a clinical observation

目的 评价89SrCl2、骨膦以及两者联合应用于治疗多发性骨转移癌的疗效。方法 以147例恶性肿瘤并多发性骨转移患者为观察对象，其中89SrCl2治疗组59例、骨膦治疗组56例、89SrCl2和骨膦联合治疗组32例，所有病例均随访观察3个月。结果 89SrCl2治疗组和骨膦治疗组对骨痛缓解总有效率分别为81.4%和80.4%，对骨病变有效率分别为17%和9%，生活质量改善率分别为49.2%和44.6%，两组3个指标比较均无显著性差异（P>0.05）。而联合应用89SrCl2和骨膦治疗组镇痛总有效率为90.6%，与前两组相比无显著性差异（P>0.05），对骨病变有效率和生活质量改善率分别为46.9%和75%，与前两组比较均有显著性差异（P<0.05）。3组病例毒副作用均较小。结论 89SrCl2和骨膦均对骨转移癌在镇痛及提高生活质量方面有较好疗效，联合应用89SrCl2和骨膦可能会进一步提高疗效，且毒副作用无明显增加。

： Objective To evalute the effect of 89SrCl2 and Bonefos, using them either separately or jointly, in the treatment of bone metastatic cancer. Method A total of 147 patients with bone metastatic cancer were enrolled in this study, who were assigned into 3 groups to receive medication with exclusive 89SrCl2 (n=59), exclusive Bonefos (n=56) or combined use of these 2 drugs (n=32). A follow-up study lasting for 3 months was conducted. Results In view of the total pain-relief rates of the bone, 89SrCl2, Bonfos and their combined use did not make significant difference (81.4%, 80.4% and 90.6%, respectively and in that order, P<0.05). As for the rates of the bone lesion improvement,17%, 9% and 46.9% were achieved through the 3 medication protocols respectively, showing significantly better effect produced by the combination of the 2 drugs (P<0.05). The same was with the rates of improvement in the quality of life, when combined medication yielded a rate as much as 75%, significantly better than that of their separate uses (49.2% and 44.6%, respectively, P<0.05). The side effects were minimal in all the cases. Conclusion 89SrCl2 and Bonefos were both effective and safe for treating bone metastatic cancer, and their combined use can produce more desirable effects.